ENXTAM:PHARM
ENXTAM:PHARMBiotechs

Why Pharming Group (ENXTAM:PHARM) Is Up 22.9% After Raising Guidance and Leniolisib’s FDA Progress

On November 6, 2025, Pharming Group N.V. reported strong quarterly earnings with nine-month sales of US$269.6 million, up from US$204.53 million the previous year, and raised its full-year 2025 revenue guidance to between US$365 million and US$375 million. A key development was the company's announcement that the FDA granted priority review for leniolisib's potential pediatric label expansion, signaling further growth opportunities for its rare disease portfolio. With robust revenue momentum...
ENXTAM:INPST
ENXTAM:INPSTLogistics

Can InPost (ENXTAM:INPST) Sustain Growth as Profit Margins Narrow Amid Rising Sales?

InPost S.A. recently reported its financial results for the third quarter and nine months ended September 30, 2025, showing sales of PLN 3,768.9 million and PLN 10,254.2 million, respectively, with net income and earnings per share declining compared to the previous year. A key insight from these results is that while sales continued to grow significantly, profitability and earnings per share both decreased from the prior period, highlighting a complex picture for the company's financial...
ENXTAM:PRX
ENXTAM:PRXMultiline Retail

Is Prosus Still a Smart Bet After Its 53.9% Gain and Tech Portfolio Shakeup?

Ever wondered if Prosus could be your next smart investment? Let’s pull back the curtain on its true value and see if the current price stacks up to reality. After a standout year with gains of 53.9%, Prosus’ shares have seen some recent volatility, dipping 1.6% in the past week and 5.5% over the past month. However, they remain up an impressive 52.7% year-to-date. Behind these moves, market watchers are eyeing news like Prosus’s continued tech investments and portfolio reshuffling, as well...
ENXTAM:PHARM
ENXTAM:PHARMBiotechs

Pharming Group (ENXTAM:PHARM): Reassessing Valuation After Upbeat Revenue Outlook and Earnings Turnaround

Pharming Group (ENXTAM:PHARM) caught investors’ attention after raising its revenue outlook for 2025, now forecasting up to USD 375 million. This move follows impressive year-over-year sales growth and a significantly smaller net loss. See our latest analysis for Pharming Group. Pharming Group’s upbeat revenue guidance and narrowing net loss have clearly caught the market’s attention, with the share price leaping over 24% in a day and posting a remarkable 42.5% year-to-date gain. Over the...
ENXTAM:MT
ENXTAM:MTMetals and Mining

ArcelorMittal (ENXTAM:MT): Assessing Valuation After a 47.85% Share Price Rally in 2024

ArcelorMittal (ENXTAM:MT) has seen solid movement in its stock price in recent months, catching the interest of investors looking at trends in the steel sector. The company’s overall performance invites a closer look at its valuation and prospects. See our latest analysis for ArcelorMittal. ArcelorMittal’s share price has charged up an impressive 47.85% so far this year, with the recent 15.48% three-month return giving investors plenty to talk about. Momentum seems to be building again, which...
ENXTAM:AMG
ENXTAM:AMGMetals and Mining

AMG Critical Materials (ENXTAM:AMG): How Bullish Narratives Look After Latest Results

AMG Critical Materials (ENXTAM:AMG) posted a strong set of headline numbers, with earnings forecast to grow 39.9% per year, well ahead of the Dutch market’s 11.2% growth rate. Revenue, meanwhile, is expected to rise 4.7% annually, trailing the broader market’s 7.8%. The company has recently returned to profitability and has grown earnings by 7.4% per year over the past five years.
ENXTAM:PHIA
ENXTAM:PHIAMedical Equipment

Philips (ENXTAM:PHIA) €446 Million One-Off Loss Tests Bullish Turnaround Narratives

Koninklijke Philips (ENXTAM:PHIA) just reported that its revenue is forecast to grow at 4.2% per year, trailing behind the broader Dutch market’s expected 7.8% yearly pace. After averaging a sharp 34.8% annual earnings decline over the last five years, the company has flipped back to profitability this year, though a one-off loss of €446 million in the past 12 months put a notable dent in recent results. Now, analysts are betting on earnings to jump by 35.19% per year, with profit growth set...
ENXTAM:HEIA
ENXTAM:HEIABeverage

Heineken (ENXTAM:HEIA): Exploring Valuation Gaps as Shares Show Renewed Momentum

Heineken (ENXTAM:HEIA) shares have shown modest movement over the past month, trading at around €68.44. Investors are weighing recent performance alongside the company’s solid annual revenue and net income growth as the outlook for the beverage sector evolves. See our latest analysis for Heineken. Heineken’s 1-month share price return of 3.7% hints at improved sentiment as investors look past a tough 12 months, where the total shareholder return is still down 5.2%. Momentum appears to be...
ENXTAM:WKL
ENXTAM:WKLProfessional Services

Does the 33.6% Drop in 2025 Signal Opportunity for Wolters Kluwer Investors?

Wondering if Wolters Kluwer’s stock offers real value right now? You’re not alone. Let’s dig into what the numbers and recent shifts actually mean for investors. Despite a strong run over the past five years (up 57.8%), shares have slipped by 3.3% in the last week and are now down 33.6% year-to-date, suggesting sentiment and risk perception may be changing. Much of this movement has been driven by broader market volatility and sector rotation among European professional services stocks...
ENXTAM:DSFIR
ENXTAM:DSFIRChemicals

DSM-Firmenich (ENXTAM:DSFIR): Assessing Valuation as Drug Delivery Innovations Take the Spotlight at PODD

DSM-Firmenich (ENXTAM:DSFIR) is set to present at the upcoming Partnership Opportunities in Drug Delivery (PODD) conference in Boston. Investors are watching closely, interested in potential updates on innovative drug delivery technologies. See our latest analysis for DSM-Firmenich. DSM-Firmenich’s scheduled appearance at PODD comes after a tough run for investors, with the 1-year total shareholder return sliding 33.9%. Recent momentum has faded, and shares sit at €69.8, reflecting a 28%...
ENXTAM:ADYEN
ENXTAM:ADYENDiversified Financial

Does Adyen’s Latest Retail Partnerships Justify Its Current Share Price?

Wondering whether Adyen’s current stock price offers real value, or if you could be overpaying? You’re definitely not alone in that curiosity. In the past year, Adyen’s stock has edged up only 3.0%, and it has hardly moved this month. This hints at shifting investor sentiment and new questions around growth and risk. Headlines have focused on Adyen’s continued expansion into new markets and partnerships with major retailers. This has sparked fresh debate around the future of digital payments...
ENXTAM:PHIA
ENXTAM:PHIAMedical Equipment

Philips (ENXTAM:PHIA): Examining Share Valuation After Recent Financial Results

Koninklijke Philips (ENXTAM:PHIA) has seen its share price hold steady recently, with investors looking over the company’s latest financial results and ongoing business performance. Philips continues to generate discussion regarding its earnings and market position. See our latest analysis for Koninklijke Philips. Philips’ share price has been rangebound so far this year, reflecting mixed investor sentiment following recent results and last year's volatility. While the year-to-date share...
ENXTAM:JDEP
ENXTAM:JDEPFood

JDE Peet's Valuation in Focus as Stock Surges 89% on Global Coffee Push

Wondering if JDE Peet's stock is a great deal right now? You are not alone, especially as more investors are eyeing its recent moves. This year, the stock has surged an impressive 89%, and it is up 64.7% over the past 12 months, suggesting the market may be rethinking its growth and risk profile. Recent headlines have highlighted JDE Peet’s push to expand its global coffee presence and efforts to strengthen its sustainability commitments. Both developments have captured investor interest and...
ENXTAM:UMG
ENXTAM:UMGEntertainment

Universal Music Group (ENXTAM:UMG): Evaluating Valuation Following AI Platform Deal and Copyright Settlement

Universal Music Group (ENXTAM:UMG) and AI music startup Udio have settled a copyright dispute and are teaming up to create a new AI-powered music platform in 2026. This collaboration signals a shift for UMG toward integrating advanced technology solutions in music creation. See our latest analysis for Universal Music Group. Following the news of Universal Music Group’s AI partnership, shares have seen some volatility, with a 6.8% slide over the past month but a modest 1.2% gain in total...
ENXTAM:FLOW
ENXTAM:FLOWCapital Markets

Flow Traders (ENXTAM:FLOW): Assessing Valuation After Q3 Miss and $275M New Credit Facility

Flow Traders (ENXTAM:FLOW) released its third-quarter results, falling short of market expectations as weak revenue capture and lower net trading income weighed on profits. The company also closed $275 million in new credit facilities to support future initiatives. See our latest analysis for Flow Traders. Shares in Flow Traders have struggled to build momentum lately, sliding 6.7% after the Q3 miss and now down more than 8% over the past month. While the 1-year total shareholder return is...
ENXTAM:DSFIR
ENXTAM:DSFIRChemicals

Should DSM-Firmenich's Q3 EBITDA Growth and Business Divestment Shape Investor Decisions? (ENXTAM:DSFIR)

On October 30, 2025, DSM-Firmenich reported solid third-quarter growth, a significant increase in Adjusted EBITDA, and provided updates on its ongoing €1 billion share repurchase program and the planned exit from its Animal Nutrition & Health business, with the divestment on track to conclude in the fourth quarter. The company also revised its full-year outlook due to unfavorable foreign exchange effects and continued volatility in vitamins, reflecting the operational challenges of its...
ENXTAM:ARCAD
ENXTAM:ARCADProfessional Services

Can Arcadis' (ENXTAM:ARCAD) Portfolio Shift Unlock Durable Growth Beyond Recent Buybacks?

In late October 2025, Arcadis N.V. repurchased 61,852 of its own shares as part of its recently announced capital reduction program, bringing total buybacks under this initiative to 448,008 shares to date. The company also reported a return to organic growth in Q3 2025, achieving €936 million in net revenues and an operating EBITA margin expansion to 11.6%, driven by portfolio shifts toward energy, water, climate, and technology markets with strong demand in North America and Europe. To...
ENXTAM:ASM
ENXTAM:ASMSemiconductor

A Fresh Look at ASM International (ENXTAM:ASM) Valuation Following Recent Share Price Rally

ASM International (ENXTAM:ASM) shares have moved higher recently, catching some attention among semiconductor investors. With strong momentum over the past month and quarterly gains topping 35%, the company’s performance continues to fuel curiosity about its valuation and growth outlook. See our latest analysis for ASM International. Momentum has clearly returned to ASM International, with the stock’s recent rally building on a robust 90-day share price return of nearly 36%. That short-term...